ABBV — Expiration of Patent US8962629 for RINVOQ
Jan 15, 2031, 12:00:00 AM UTC
Summary
Patent US8962629 for RINVOQ, assigned to AbbVie Inc, is set to expire on January 15, 2031, potentially impacting the product's market exclusivity and opening the door to increased competition within the immunomodulator market. RINVOQ is used to treat various immunological and oncological conditions, and the expiration may lead to the introduction of generic alternatives, affecting AbbVie's revenue streams and market position.
Company
ABBVIE INC (ABBV)NYSE — Healthcare: Manufacturing, Drug Manufacturers - General: Pharmaceutical Preparations
www.abbvie.comSimilar Events
Expiration of Patent US11607411 for RINVOQ
AbbVie Inc's patent US11607411 for RINVOQ, which addresses treatment methods for Crohn's disease and ulcerative colitis using a JAK1 inhibitor, is set to expire on March 9, 2038. The expiration of this patent may open the door for generic versions of the drug, potentially impacting AbbVie's market position and revenues significantly as competition increases. RINVOQ is a key product in AbbVie's portfolio that has shown potential in providing clinical remission for patients with inflammatory bowel diseases.
Patent expirationExpiration of Patent US10550126 for RINVOQ
The patent US10550126 for RINVOQ, a drug developed by AbbVie Inc used in the treatment of rheumatoid arthritis and atopic dermatitis, is set to expire on October 17, 2036. This expiration may allow for increased competition in the market, potentially impacting AbbVie's revenue from RINVOQ as generic alternatives become available.
Patent ExpirationPatent Expiration for RINVOQ (USRE47221)
AbbVie Inc. anticipates the expiration of its patent USRE47221 for RINVOQ on August 16, 2033. This patent covers compounds useful for treating immunological and oncological conditions. The expiration could potentially impact AbbVie's competitive advantage and market share for RINVOQ, which is a key product in their portfolio.
Patent ExpirationExpiration of Patent US8778997 for RAPIVAB
The patent US8778997 for RAPIVAB, assigned to Biocryst Pharmaceuticals Inc, is set to expire on May 7, 2027. RAPIVAB is designed for treating viral infections, making the patent's expiration significant as it may lead to increased competition and potential generic alternatives in the market. This could impact Biocryst's revenue streams associated with RAPIVAB following patent expiration.
Patent ExpirationExpiration of Patent US8809292 for LEQVIO
Alnylam Pharmaceuticals Inc and Novartis Pharmaceuticals Corp's patent US8809292 related to LEQVIO is set to expire on May 10, 2027. LEQVIO is a double-stranded ribonucleic acid (dsRNA) designed to inhibit the expression of the PCSK9 gene, which is associated with cholesterol regulation. The expiration of this patent may allow for increased competition in the market, potentially impacting revenue for the associated companies as generic versions could become available.
Patent ExpirationExpiration of Patent US9370582 for LEQVIO
The patent US9370582 for LEQVIO, assigned to Alnylam Pharmaceuticals Inc and Novartis Pharmaceuticals Corp, is set to expire on December 4, 2028. LEQVIO is an innovative drug designed to target specific RNA sequences, potentially altering gene expression related to various diseases. The expiration of this patent may allow for generic versions of the drug to enter the market, affecting proprietary sales and pricing strategies for both companies involved. Investors should monitor subsequent developments regarding generic competition following the patent's expiration.
Patent ExpirationExpiration of Patent US10391075 for RAPIVAB
Patent US10391075 pertaining to RAPIVAB, a treatment for viral infections, assigned to Biocryst Pharmaceuticals Inc, is set to expire on February 12, 2027. This expiration may impact the competitive landscape for Biocryst, potentially allowing for the introduction of generic alternatives, which could affect the company's future sales and market position.
Patent ExpirationExpiration of Patent US11844858 related to RYZUMVI
The patent US11844858 related to the product RYZUMVI, which involves aqueous ophthalmic solutions of phentolamine for enhancing visual performance, is set to expire on January 31, 2034. This expiration may significantly impact the product's market exclusivity, potentially leading to increased competition in the ophthalmic solutions market. The patent is assigned to Opus Genetics Inc and FAMYGEN LIFE SCIENCES INC.
Patent ExpirationExpiration of Patent US10851377 for LEQVIO
The patent US10851377 for LEQVIO, assigned to Alnylam Pharmaceuticals Inc and Novartis Pharmaceuticals Corp, is set to expire on August 25, 2036. This patent covers methods for inhibiting the expression of the PCSK9 gene, which is significant for treating lipid disorders such as hyperlipidemia using RNA interference technology. The expiration of this patent may lead to increased competition in the market for lipid-altering therapies, potentially affecting the financial performance of the involved companies.
Patent Expiration